Clinical Trial Update: Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating treosulfan (Trecondi Ideogen) in patients with multiple myeloma, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Treosulfan (Trecondi Ideogen) (treosulfan)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING